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Abstract
Bone is the most common site for breast cancer spread. In the pro-metastatic cell line 1833, derived from MDA-MB-231
breast adenocarcinoma cells, both hypoxia and hepatocyte growth factor (HGF) inﬂuence the effect of miR-125b on
ETS proto-oncogene 1 transcription factor (ETS1). The effect of hypoxia inducible factor 1 alpha subunit (HIF1A), known
to promote metastatic spread by upregulating prostaglandin endoperoxide synthase 2 (PTGS2), may be dampened by
miR-125b targeting PTGS2. Here, we investigated whether miR-125b plays a role in breast cancer metastasis by
measuring its activity in response to the chemotherapeutic agent NS-398 in a xenograft model. NS-398 is typically
used in the clinic to target PTGS2. We also aimed to describe the molecular mechanisms in vitro, since the
enhancement of epithelial properties may favor the efﬁcacy of therapies. We report that in the xenograft model, miR-
125b reduced metastasis to the bone. We also report suppression of PTGS2 enhanced survival by decreasing HIF1A in
cells within the bone marrow. In 1833 cells transfected with a miR-125b mimic we observed several phenotypic
changes including enhancement of the epithelial marker E-cadherin, a reduction of mesenchymal-associated genes
and a reduction of WNT-associated stem cell signaling. Our ﬁndings suggest that in vivo, key players of the bone
microenvironment promoting breast cancer spread are regulated by miR-125b. In future, biological molecules
imitating miR-125b may enhance the sensitivity of chemotherapeutic agents used to counteract bone metastases.
Introduction
Disseminated tumor cells (DTC) from breast carcinoma
coordinate the formation of a favorable microenviron-
ment for future bone metastases, and the bone marrow is
implicated through growth factors and various cellular
types of the staminal hematopoietic and osteoblastic
niches1,2. The presence of micrometastases, within the
bone marrow premetastatic niche, is used as a predictive
index for the survival of breast carcinoma patients;
micrometastasis evolution leads to osteolytic metastases,
involving the osteoclast-mediated reactivation of dormant
metastatic cells3,4. Xenograft models are suitable to
examine the molecular modiﬁcations in metastatic cells,
supportive cells and extracellular matrix (ECM), which
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underlie the interaction between metastasis and stroma.
Novel therapeutic approaches might counteract the
favorable milieu of components in diseased bone after the
DTC access5,6.
Microenvironmental stimuli contribute to the pheno-
type plasticity, which is critical for the metastatic process
of DTC engrafted in the skeleton6–9. In human bone
metastasis specimens, the hepatocyte growth factor
(HGF)/Met receptor signaling pathway correlates with
miR-34a down-regulation10. Since miRNAs play a role in
mRNA degradation or decrease of protein expression, and
this is consequence of the binding to the 3′-untranslated
region (3′UTR) (post-transcriptional level)11,12, miR-34a
seems to target Met in skeleton metastases but not in the
pair-matched primary breast carcinomas10.
The knowledge of miRNA functions in bone metastasis
phenotype would be important for therapeutic pur-
pose13,14. miRNA deregulation seems to depend on the
microenvironment stimuli and/or on epigenetic control,
and miRNA changes might inhibit or induce the epithelial
phenotype affecting invasion and metastasis15–17. The
weakening of tumor cells adhesion, and the strengthening
of cell motility and proteolysis trigger
epithelial–mesenchymal transition (EMT) and invasion.
Notably, the mesenchymal phenotype and stemness are
associated with neoplasia resistance to therapy7,18–20.
The miR-125b suppresses the osteogenic differentiation
of mesenchymal stem cells derived from bone marrow21,
and it targets speciﬁc signaling pathways such as those
regulated by ETS proto-oncogene 1 transcription factor
(ETS1)13. In 1833 bone metastatic cells, derived from
MDA-MB-231 breast adenocarcinoma cells, the effects of
miR-125b on ETS1 activity and on the biological func-
tions are inﬂuenced by HGF and hypoxia, which are sti-
muli of the bone microenvironment22. miR-125b acting as
a tumor suppressor may translationally repress Human
antigen R (HuR), which affects the stability and transla-
tional efﬁciency of target mRNAs11. Thus, the expression
of genes such as prostaglandin endoperoxide synthase 2
(PTGS2) (previously known as cyclooxygenase 2), show-
ing three HuR binding sequences in the 3′UTR11, might
be controlled by miR-125b. PTGS2 plays multiple roles in
primary tumors and bone metastases23,24. In 1833 cells,
PTGS2 is implicated in the nuclear translocation of
hypoxia inducible factor 1 alpha subunit (HIF1A) and in
HIF1 activation and, therefore, in angiogenesis important
for metastasis outgrowth25. Also, miR-125b seems to
reverse multidrug resistance by modulating anti-apoptotic
factors26. Even if some miRNA roles in cancer treatment
have been clariﬁed27, pre-clinical studies for antimeta-
static therapies based on miRNA mimic are still lacking.
The aim of the present paper is to provide the molecular
basis for the design of novel combined therapies to switch
metastatic cells towards the epithelial phenotype,
reducing also stem cell properties: this tool would permit
to enhance the sensitivity to chemotherapeutic agents.
Thus, the xenograft model of bone metastasis was pre-
pared with 1833 cells transfected with miR-125b mimic,
and the PTGS2 inhibitor N-(2-cyclohexyloxy-4-nitro-
phenyl)methanesulfonamide (NS-398) was administered
to the mice28. miR-125b mimic might hamper bone
metastasis colonization, by down-regulating ETS1 and
probably by affecting indirectly epithelial and stemness
genes11,13,29, and might enhance the inhibitory effect of
anti-PTGS2 chemotherapy. We studied E-cadherin, which
is a marker of epithelial phenotype of skeleton metastasis
from breast carcinoma18,19,30, while the mesenchymal
markers examined were matrix metalloproteinase2
(MMP2), essential for dissemination of metastatic cells by
remodeling ECM (basal membrane and interstitial
matrix), and vimentin which promotes adhesion/moti-
lity19,20. The WNT pathway activity would indicate the
acquirement of stem cell properties, and it is targeted by
miRNAs downstream of ETS118,29. We expect that miR-
125b might interrupt the interaction between ETS1 and
HIF1A22, impairing directly and/or indirectly PTGS2,
which is a target gene of HIF125. ETS1 acts as a player for
the invasive program depending on the conditions of the
osseous microenvironment22,31.
Under miR-125b and NS-398 combined treatment, we
observed the reduction and delay of bone metastasis
outgrowth, and decreases of the expression of ETS1,
HIF1A and PTGS2 together with phenotypic changes. In
vitro, hypoxia and HGF interfered in the changes of gene
expression due to miR-125b.
Results
Effect of miR-125b and NS-398 on bone metastasis growth
Considering that miR-125b targets a wide spectrum of
genes including PTGS2 and ETS1, and that miRNAs are
proposed as tools for cancer therapy, we tested miR-125b
alone or in combination with NS-398, a speciﬁc chemical
inhibitor of PTGS228. In Figs. 1 and 2, we evaluated the
growth of bone metastasis and the survival of the xeno-
graft mice under these treatments. To prepare the xeno-
graft model, we used 1833-bone metastatic cells
engineered with the triple reporter construct with lumi-
nescence (1833/TGL)32.
As shown in Fig. 1a, we performed the time-course of
bioluminescence images to evaluate the bone-metastasis
development after 1833/TGL injection (ME): ME was the
control mice group, and the effects of the single treat-
ments or their combination were evaluated in respect to
ME. Similar bioluminescence signals were observed for
ME and for the xenograft mice injected with miR-neg-
CTR cells (data not shown).
After quantiﬁcation of the bioluminescence, the values
for the hind limbs were reported in Fig. 1b. All the
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treatments did not practically affect metastatic growth
within 4 days from 1833/TGL injection. At 9 days, miR-
125b alone or in combination with NS-398 markedly
prevented metastasis development, in respect to ME and
to NS-398 alone. Importantly, only for the combination
miR-125b plus NS-398 this strong inhibitory effect per-
sisted until 21 days.
In addition, we demonstrated by micro-computed
tomography (μCT) analysis of the hind limbs that miR-
125b plus NS-398 was effective in preventing at a great
extent the osteolytic lesions at 21 days, making the
comparison with ME at the same time (Fig. 1c). The single
treatments signiﬁcantly reduced osteolysis at 21 days in
the hind limbs. Of note, in the mice treated with miR-
125b plus NS-398 the osteolytic lesions were evidenced
again at 33 days (Fig. 1c). Consistently, the metastasis
wideness was less at 26 days than at 29 days, and the
bioluminescence signal at 26 days was reduced of about
60% by the combined treatment (Supplementary
Figure S1).
Figure 2a shows that the exposure to miR-125b plus
NS-398 prolonged the mice survival of about 12 days in
respect to that of ME, and the life-protective effect of the
therapy combination was evident also in comparison with
the single treatments.
Based on these data, we examined by immunohis-
tochemistry at 26 days the expression of the target genes
of miR-125b as well as of HIF1A, known to be implicated
in PTGS2 regulation via HIF1 activity (Fig. 2b)25. A
semiquantitative evaluation of the immunohistochemistry
data was performed, considering low (2+), mild (3+),
high (4+) and very high (5+) signals. The expression of
ETS1 and HIF1A was more elevated than that of PTGS2
in ME-bone metastases: these gene signals were strongly
Fig. 1 miR-125b alone or in combination with NS-398 affected bone metastasis formation in the xenograft mice. a Representative
bioluminescence imaging (BLI) of the xenograft mice treated as shown. ME, mice bearing bone metastases. b We report quantitative data for the
bioluminescence signals, and the percent of inhibition due the treatments vs. ME. The data are the means ± S.E. of ﬁve mice per group. *P < 0.05, ***P
< 0.001 vs. the bioluminescence value of ME at the corresponding time; °°P < 0.005 vs. the value under NS-398 treatment at the corresponding time;
◊P < 0.05, ◊◊P < 0.005 vs. the value under miR-125b at the corresponding time. c Representative images of the three-dimensional reconstruction of
μCT at 21 and 33 days of treatment. Three xenograft mice per group were analyzed with similar results. The arrows indicate osteolytic lesions
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reduced (from 50 to 80%) by the combined exposure to
miR-125b plus NS-398, while the single treatment miR-
125b or NS-398 seemed less effective.
Altogether, our ﬁndings suggested a key role of the
genes examined in bone metastasis growth, and the efﬁ-
cacy of the combined treatment tested.
Expression of ETS1, HIF1A and PTGS2 and their
intracellular distribution in bone metastasis under miR-
125b plus NS-398
Immunohistochemistry images of the genes examined
are shown in Figs. 3–5. As reported in Fig. 3 and in
Supplementary Figure S2, the expression of ETS1 was
very high in bone-metastasis both at cytosol and nuclear
levels (inset). ETS1 was elevated also in the cytosol of
supportive cells of the bone marrow, while in the normal
bone the ETS1 signal was scarce (Supplementary Fig-
ure S2). The miR-125b plus NS-398 treatment reduced
mostly metastatic ETS1, including the nuclear signal
(Fig. 3, insets). As shown in Fig. 4, in bone metastases
under the combined treatment, the expression of HIF1A
largely diminished at cytosol and nuclear levels (insets);
the signal of HIF1A extensively decreased also in the
cytosol of the bone marrow supportive cells. PTGS2 signal
in bone metastases was mild, showing prevalent cytosolic
localization, and it was low in the bone marrow: the
combined treatment almost completely reduced the signal
in the two compartments (Fig. 5). Negative controls did
not show speciﬁc signals (Figs. 3–5).
The effect of miR-125b or NS-398 treatment on ETS1,
HIF1A and PTGS2 is reported in Supplementary Fig-
ures S3-S5.
In 1833 cells miR-125b mimic affected gene expression
under the inﬂuence of hypoxia or HGF
In vitro experiments were performed to better under-
stand the molecular mechanisms underlying miR-125b
effects in the bone metastasis xenograft model, and to
clarify whether microenvironmental stimuli might play a
key regulatory role. To this purpose, in 1833 cells trans-
fected with miR-125b and exposed to hypoxia or HGF, we
monitored epithelial, mesenchymal and stem cell mar-
kers7,18, i.e., E-cadherin, MMP2, vimentin and WNT-
pathway activity (Fig. 6). Also, we examined the expres-
sion of PTGS2, ETS1 and HIF1A, direct or indirect target
genes of miR-125b, as well as of Secreted acidic and rich
in cysteine (SPARC) and of osteocalcin, which seem
involved in osteoblastic niche (Figs. 6 and 7)33,34. Since we
have recently shown that ETS1 expression vector affects
HIF1A transactivation22, miR-125b targeting ETS1 might
inﬂuence HIF1A expression.
miR-125b mimic augmented the E-cadherin expression
only in the presence of 10% fetal bovine serum (FBS): this
effect was counteracted by the concomitant exposure to
hypoxia (Fig. 6a). Differently, HGF enhanced E-cadherin
in 1833 cells transfected with miR-CTR, and miR-125b
reduced E-cadherin under basal and HGF conditions.
Hypoxia induced MMP2 and vimentin, while being
prevented by concomitant miR-125b transfection. Also,
miR-125b showed inhibitory effects on MMP2 and
vimentin under 0.1% FBS, and HGF caused a reversion
(Fig. 6a).
TOPFLASH-gene reporter was used to evaluate WNT
pathway activity35 (Fig. 6b). miR-125b alone inhibited of
about 40% the luciferase activity, while in the presence of
hypoxia or HGF a reversion of TOPFLASH activity was
observed, peaking (2.5-fold) under hypoxia.
In the nuclei of the cells transfected with miR-CTR, the
long-time exposure to hypoxia gave a huge HIF1A
increase, and HGF tripled HIF1A: these increases were
partly prevented by the concomitant miR-125b treatment.
The transfection of miR-125b under 10% FBS (upper
panel) and 0.1% FBS (lower panel) doubled HIF1A in the
cytosol (Fig. 6c).
Altogether, the 1833 cells required the serum presence
for the miR-125b-dependent stimulation of the epithelial
marker E-cadherin, while the miR-125b negative effects
towards the mesenchymal markers MMP2 and vimentin,
the staminal WNT pathway and nuclear HIF1A occurred
both under 10 and 0.1% FBS. Also, the reduction of
Fig. 2 Effect of miR-125b, NS-398 and their combination on
xenograft mice survival, and on gene expression in bone
metastasis. a Survival curve on Kaplan-Meier plots of the data of
treated and untreated ME. b Semi-quantitative evaluation of
immunohistochemistry assays of ETS1, HIF1A and PTGS2 in bone
metastasis of xenograft mice treated as indicated. We analyzed serial
sections for each specimen from three mice per group of treatments
at 26 days, and we found similar results
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Fig. 3 miR-125b in combination with NS-398 affected ETS1 expression in bone metastasis of xenograft mice.We show representative images
of ETS1 in bone metastasis from mice treated with the combination miR-125b plus NS-398, or not (ME). Serial sections for each specimen from three
mice at 26 days were analyzed obtaining similar results. me, metastasis; bm, bone marrow; bo, bone. Scale bar= 120 μm (reported in 40×
magniﬁcation panels). Scale bar= 60 μm (reported in the three insets). The negative control was performed without the speciﬁc antibody
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nuclear HIF1A by miR-125b in the presence of hypoxia or
HGF, was consistent with the immunohistochemistry
ﬁndings (Supplementary Figure S4).
Figure 7a shows that 36-h hypoxia doubled the ETS1
protein level in 1833 cells, but not when miR-CTR was
transfected. miR-125b in the presence or the absence of
Fig. 4 HIF1A expression in bone metastasis of xenograft mice under miR-125b in combination with NS-398. We show representative images
of HIF1A in bone metastasis of mice treated with the combination miR-125b plus NS-398, or not (ME). Serial sections for each specimen from three
mice at 26 days were analyzed obtaining similar results. me, metastasis; bm, bone marrow; bo, bone. Scale bar= 120 μm (reported in an
exempliﬁcative panel). The negative control was performed without the speciﬁc antibody
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hypoxia down-regulated ETS1 (p51/52), while the p27
form of ETS1 was unchanged by the treatments tested.
PTGS2, SPARC and osteocalcin were induced by hypoxia
in 1833 cells transfected or not with miR-CTR: miR-125b
largely prevented the stimulatory effects of hypoxia
(Fig. 7b). The consensus sequences for transcription factors
in osteocalcin and SPARC promoters are reported in Sup-
plementary Figure S6: the numerous ETS1 and Runx2
binding sites shown might explain the efﬁcacy of the
treatments affecting metastasis phenotype. Putative binding
Fig. 5 miR-125b in combination with NS-398 affected PTGS2 expression in bone metastasis of xenograft mice. We show representative
images of PTGS2 in bone metastasis of mice treated with the combination miR-125b plus NS-398, or not (ME). Serial sections for each specimen from
three mice at 26 days were analyzed obtaining similar results. me, metastasis; bm, bone marrow; bo, bone. Scale bar= 120 μm (reported in an
exempliﬁcative panel). The negative control was performed without the speciﬁc antibody
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sites of Twist and Snail were also present in the two gene
promoters, suggesting a relationship between the changes of
gene expression and the metastatic phenotype.
miR-125b transfection, in the presence or the absence of
HGF, down-regulated both the p51/52 and the p27 forms
of ETS1. In 1833 cells, HGF induced the dominant
negative p27, which might interfere in ETS1 activity
(Fig. 7c).
The pattern of ETS1 under HGF or hypoxia in vitro was
in agreement with that observed in vivo, indicating the
Fig. 6 Effect of miR-125b on epithelial and mesenchymal markers and on HIF1A expression under hypoxia or HGF in 1833 cells. a
Histograms of Western blots densitometric data; the experiments were repeated three times and the means ± S.E. are shown. Vinculin was used for
normalization. ΔP < 0.05, ΔΔP < 0.005 vs. miR-CTR; *P < 0.05 vs. miR-125b. Also, we report the representative images of the Western blots. b TOPFLASH
luciferase activity is shown. The assays were performed in triplicate, and were repeated three times; the data are shown as the means ± S.E. ΔP < 0.05
vs. miR-CTR; *P < 0.05 vs. miR-125b. c Representative images of Western blots performed in triplicate are shown. Vinculin and B23 were used for
normalization. The data of densitometric analysis are reported in the table as fold-variations vs. the ﬁrst lane, considered 1. ΔP < 0.05, ΔΔP < 0.005 vs.
miR-CTR; *P < 0.05 vs. miR-CTR plus hypoxia or plus HGF; §P < 0.05, §§P < 0.005 vs. miR-125b
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Fig. 7 A gene pattern for adhesion/invasion of 1833-bone metastatic cells was affected by miR-125b under hypoxia, or HGF treatment. a
Representative images of Western blots repeated three times are shown. Vinculin was used for normalization. The data of densitometric analysis are
reported in the table as fold-variations vs. the ﬁrst lane, considered 1. *P < 0.05 vs. untreated 1833 cells; ΔP < 0.05 vs. miR-CTR; §P < 0.05 vs. miR-CTR
under hypoxia. b Representative images of Western blots repeated three times are shown. Vinculin was used for normalization. The numbers at the
bottom indicate the fold-variations vs. the ﬁrst lane, considered 1. *P < 0.05, **P < 0.005 vs. untreated 1833 cells; ΔP < 0.05, ΔΔP < 0.005 vs. miR-CTR; §P
< 0.05 vs. miR-CTR under hypoxia. c Representative images of Western blots repeated three times are shown. Vinculin was used for normalization. The
data of densitometric analysis are reported in the table as fold-variations vs. the ﬁrst lane, considered 1. *P < 0.05 vs. untreated 1833 cells; ΔP < 0.05 vs.
miR-CTR; §P < 0.05 vs. miR-CTR under HGF. d Representative images of Western blots repeated three times are shown. Vinculin was used for
normalization. The numbers at the bottom indicate the fold-variations vs. the ﬁrst lane, considered 1. *P < 0.05 vs. untreated 1833 cells; ΔP < 0.05, ΔΔP
< 0.005 vs. miR-CTR; §P < 0.05 vs. miR-CTR under HGF. e To make a comparative evaluation of the gene effects of miR-125b under hypoxia or HGF, we
show the histograms of the densitometric values of the Western blots for PTGS2, SPARC and osteocalcin. The data are the means ± S.E. of three
separate experiments. ΔP < 0.05, ΔΔP < 0.005 vs. respective miR-CTR transfected cells; §P < 0.05 vs. respective miR-125b transfected cells
Maroni et al. Cell Death and Disease  (2018) 9:472 Page 9 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
important role played by these microenvironmental sti-
muli in the inhibitory effect of miR-125b towards ETS1 in
the xenograft model (Supplementary Figure S3). Only
under HGF but not in hypoxic conditions the ETS1-p27
form decreased when the 1833 cells were transfected with
miR-CTR or miR-125b.
PTGS2 and SPARC were induced by miR-125b plus
HGF; osteocalcin was strongly down-regulated by star-
vation, and incremented under miR-125b plus HGF
(Fig. 7d).
In conclusion, in the histograms (Fig. 7e) we compared
the effects of miR-125b under the two microenviron-
mental stimuli on PTGS2, SPARC and osteocalcin.
SPARC is a matricellular protein, not really an ECM
component, which might participate in the stiffness and
the release of growth factors36, initiating changes in
neoplastic cell phenotype with an involvement of miR-
NAs37. Osteocalcin is important for the osteoblastic
mineralization of endosteal-like ECM: the endosteum
lines the inner wall of long bones surrounding the bone
marrow cavity, and drives the cellular changes for osteo-
lytic metastases4,33. Normally, osteocalcin is produced
exclusively by osteoblasts, acting in the bone matrix as a
non-collagenous protein, and is now considered an inhi-
bitor of bone mineralization even if opposite hypotheses
cannot be excluded38. By considering PTGS2 and SPARC,
miR-125b was stimulatory in the presence of HGF and
inhibitory under hypoxia. Osteocalcin seemed strongly
hampered by miR-125b, mostly under starvation, with a
partial reversion both under HGF and hypoxia. Thus, the
effect of miR-125b on target genes seemed to depend on
microenvironmental stimuli.
Discussion
In the 1833 xenograft model of skeleton metastasis from
breast carcinoma the concomitant exposure to miR-125b
mimic and NS-398, a speciﬁc PTGS2 chemical inhibitor,
reduced and delayed the outgrowth of osteolytic bone
metastases prolonging mice survival in respect to the
single treatments. The miR-125b strongly enhanced the
life-protective effect of NS-398, and we hypothesize that
the efﬁcacy of the combined treatment depended on the
reduction of chemoresistance, known to be associated
with EMT7,18. The endpoint of our study was to
demonstrate that miR-125b enhances the epithelial-like
transition in vitro, and that the paracrine stimuli and
physical conditions might counteract or favor the phe-
notypic changes, explaining also the in vivo ﬁndings on
growth and gene expression in bone metastases.
Importantly, the adverse effect of miR-125b mimic plus
NS-398 on metastatic growth started at 4 days from 1833/
TGL-cell injection and became highly signiﬁcant at
9 days, leading to suppose that the hampering of coloni-
zation was caused by molecular and cellular modiﬁcations
at early stages after bone engraftment of DTC. The
therapeutic approach consisting in the overexpression of
miR-125b which targets a wide spectrum of genes, such as
ETS1 and PTGS2, will eventually impact clinical practice
preventing bone resorption. The exit from quiescence/
dormancy depends on osteoclast activation, and also on
stroma composition and neoangiogenic vessels4.
The molecular mechanisms underlying the therapeutic
efﬁcacy of the studied treatment miR-125b plus NS-398
would be multiple (Fig. 8). First, the blockade of the
autoregulatory loop between ETS1 and HIF1A/HIF1,
because of the reciprocal control of these transcription
factor activities22, and second a complete inhibition of
PTGS2 by the concomitant chemical and miR-125b
treatment. At support, PTGS2 signal remarkably
decreased in osseous metastases and the bone marrow,
also due to the down-regulation of HIF1A throughout the
metastatic tissue: the alpha/beta heterodimer HIF1 is a
transcription factor known to target PTGS2 and
ETS120,25. Our proposed therapy would have a direct
effect on PTGS2, through miR-125b action on HuR sites,
even if a post-transcriptional effect of miR-125b on ETS1
cannot be excluded. Also, an indirect effect of the therapy
on ETS1 through HIF1A downregulation might occur,
consistent with the decreases of ETS1 and HIF1A in
cytosol and nuclei of metastases and in the bone marrow.
We suggest that these amplifying effects might impinge
on invasion and angiogenesis, because ETS1 and PTGS2
are key players in these processes: PTGS2 through pros-
taglandin E2 regulates HIF1A nuclear translocation and
HIF1 activity (Supplementary Figure S4)20,25. Capillaries
are associated with quiescent and actively resorbing
endosteal surfaces, and are implicated in development of
bone metastasis, permitting the access of DTC to bone-
remodeling compartment or to the immediate adjacent
microenvironment4.
Third, in vivo phenotypic changes under miR-125b
plus NS-398 seemed to depend on the metastatic
Fig. 8 Effects of miR-125b on gene expression under
microenvironmental stimuli in bone metastasis
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down-regulations of ETS1 and HIF1A, which are critical
for the invasive phenotype and staminality20,39. Also, in
agreement with the hypothesis that in 1833-xenograft
model miR-125b decreased the metastasis resistance to
chemotherapy, the microenvironmental stimuli would be
critical for the effect of miR-125b in vivo, suggesting that
the bone context encountered by DTC would be funda-
mental for their fate. The skeleton microenvironment is
modiﬁed by the engraftment of metastatic cells inﬂuen-
cing the EMT18,37, and it would interfere in the therapies
such as that with miR-125b mimic.
The axis HGF/Met receptor seems to be implicated in
stroma-induced drug desensitization20, and hypoxia con-
ferring stem like properties might give resistance to
therapy39. Consistently, we found that the tumor sup-
pressor gene miR-125b in 1833 cells reduced WNT
activity and targeted transcription factors, such as ETS1,
HIF1 and WNT, likely affecting gene expression in bone
metastasis. Numerous ETS1 consensus sequences are
present in SPARC and osteocalcin promoters (Supple-
mentary Figure S6). In addition, considering that in bone-
metastatic cells miR-125b enhanced the expression of E-
cadherin, while decreasing MMP2 and vimentin, our
present results suggested a switch towards an epithelial
phenotype, which is known to be more responsive to
chemotherapy than the mesenchymal/invasive
phenotype7,18,20.
In bone metastatic cells, which show an epithelial phe-
notype30, miR-125b might antagonize the function of
miR-20040: we propose that miR-125b by blocking p53
prevents miR-200-inhibitory function11,19,37. As a con-
sequence, Twist activity might mediate the MET meta-
stable phenotype with E-cadherin expression9. The miR-
125b effect on the gene expression of bone metastatic
cells depended on serum conditions, HGF and hypoxia
exposure, favoring the reduction of ETS1 expression
in vitro, while the microenvironmental stimuli counter-
acted the miR-125b-dependent epithelial phenotype with
E-cadherin reduction by hypoxia and MMP2 and
vimentin enhancements by HGF.
Altogether, the knowledge of phenotypic changes under
therapy were further deepened by studying SPARC and
osteocalcin, which are target genes of Runx2 transcription
factor34,41; HIF1A expression is also controlled by Runx2
by preventing the ubiquitination42. Runx2 plays key roles
in bone metastasis from breast carcinoma43,44, being
regulated by Endothelin-1, HGF and hypoxia35,45. Nota-
bly, bone-metastatic cells acquire osteomimicry by pro-
ducing SPARC and osteocalcin, as shown in the 1833-
xenograft model32,34,46.
HGF and hypoxia caused SPARC accumulation, which
might be important to determine the adhesive properties
of bone metastasis in the osteoblastic niche, ECM stiffness
and growth-factor release, and miR-125b counteracted
the stimulatory effect of hypoxia. Therefore, the miR-125b
mimic might reduce bone metastasis colonization in vivo
inﬂuencing SPARC roles in metastasis plasticity and in
metastasis dormancy, by the regulation of biological and
physical properties of the ECM34,36,46,47. HIF1A beyond
SPARC participates in metastasis dormancy48.
In conclusion, a strong down-regulation of osteocalcin
was observed in the presence of miR-125b under serum
deprivation, indicating the susceptibility to growth factors,
while HGF restoration not only reversed osteocalcin
expression, but also increased PTGS2 and SPARC under
miR-125b. The miR-125b-dependent impairment of
osteocalcin, considered an inhibitor of mineralization38,
might be related to protection from osteolysis: this effect
would be partly prevented by the microenvironmental
stimuli. The combined therapeutic approach miR-125b
plus NS-398 seems promising for the early hampering
effects on metastatic growth and osteolytic lesions, con-
sidering also that the initial metastatic steps and therapy




The 1833 bone metastatic clone, derived from MDA-
MB-231 breast adenocarcinoma cells, and the 1833 cells
retrovirally transfected with HSV1-tk/GFP/ﬁreﬂy lucifer-
ase construct (1833/TGL)32, were a gift from Dr. J. Mas-
sagué (Memorial Sloan-Kettering Cancer Center, New
York, NY, USA).
The cells, routinely maintained in DMEM containing
10% FBS (Sigma-Aldrich, Saint Louis, MO), were used
after two or three passages in culture. The 1833 and 1833/
TGL cells were infected with miR-125b expression lenti-
virus (hsa-miR-125b-5p MIMAT0000423, GenTarget
Inc., San Diego, CA, USA) or with miR-CTR (negative
control, empty miR lentivirus, GenTarget Inc.), following
the manufacturer’s recommended procedures. Lentiviral
vectors co-expressed puromycin resistance for the selec-
tion of infected cells. A pilot experiment has been done to
determine the antibiotic’s kill curve for our cells. Thus,
72-h infected cells were selected with 2 μg/ml puromycin,
and were maintained under selection in all the
experiments.
In another group of experiments, ﬂasks containing 1833
cells at 70% of conﬂuence were used to transfect the
TOPFLASH gene reporter from Dr. B.M. Gumbiner
(Memorial Sloan-Kettering Cancer Center, New York,
NY, USA). For the transfection of the TOPFLASH con-
struct, we performed an incubation mixture 3:1, DNA:
Fugene 6 (Roche Diagnostics, Monza, Italy); the mixture
contained also the internal control pRL-TK (Renilla
Luciferase Plasmid). Fireﬂy/Renilla luciferase activity
ratios were calculated by the software9.
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Animal treatment
Animal studies were carried out according to the
Institutional Guide for Care and Use of Laboratory
Animals, and the Directive 2010/63/UE. All mice were
bred and maintained under speciﬁc pathogen-free con-
ditions in the institutional animal facility of the Scientiﬁc
Institute San Raffaele, Milano, Italy. All experiments were
performed with the protocol approved by the Institutional
Animal Care and Use Committee of Scientiﬁc Institute
San Raffaele and by Ministero della Salute. Anaesthetized
nu/nu mice were treated as follows: one animal group
(ME, n= 11) was injected with the 1833/TGL cells; a
second group (ME+miR-125b, n= 11) received 1833/
TGL cells infected with miR-125b; a third group (ME+
miR-125b+NS-398, n= 10) received 1833/TGL cells
infected with miR-125b, and the mice were concomitantly
injected with 20mg/kg NS-398 i.p. 5 days/week until the
suppression; the fourth group was treated only with
NS-398 (n= 10); the ﬁfth group was administered
1833/TGL cells infected miR-neg-CTR (ME+miR-CTR,
n= 4). For the xenograft model preparation, 5 × 105
infected or non-infected cells were injected to the mice,
that were monitored by Optical imaging and μCT assay6,
and were sacriﬁced to prevent the suffering. Three ani-
mals per group were sacriﬁced at the indicated times to
perform immunohistochemistry and Hematoxylin &
Eosin assays.
The injection efﬁciency for all the mice was controlled
by monitoring the bioluminescence signal 1 h after
xenografting. We normalized the data of bioluminescence
for each animal with the value obtained at 24 h. This
procedure was made to exclude a potential impact of the
pretreatments, i.e., miR-125b-cell transfection or NS-398
exposure, on extravasation and homing with an inter-
ference in the evaluation of metastasis growth.
Immunohistochemistry
Bone samples ﬁxed with 10% formalin, were decalciﬁed,
embedded in parafﬁn, and serial sections were prepared49.
To evaluate ETS1, HIF1A and PTGS2, the immunos-
taining was performed with anti-Ets-1 (1:50, C20 Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-HIF-1α
(1:100, Novus Biologicals, Littleton, CO, USA), and anti-
COX2 (1:50, Cayman Chemical, Ann Arbor, MI, USA).
Western blot assay
Some ﬂasks containing 1833 cells infected with miR-
125b mimic were exposed to hypoxia50, or to 100 ng/ml
HGF under starvation9, and total and nuclear protein
extracts were prepared. To evaluate ETS1, HIF1A and
PTGS2, immunoblots were performed with anti-Ets-1
(1:2000), anti-HIF-1α (clone54) (1:350, BD-Transduction
Laboratories, Franklin Lakes, NJ, USA), and anti-COX2
(1:100). Also, anti-E-cadherin (1:1000, clone 36
Transduction Laboratories, Bedford, MA, USA), anti-
MMP2 (1:500, Novus Biologicals, Abingdon, UK), anti-
vimentin (1:500 Santa-Cruz Biotechnology), anti-SPARC
(1:200, H-90 Santa Cruz Biotechnology), anti-osteocalcin
(5 μg/ml, Abcam, Cambridge, UK), anti-B23 (1:1000,
H106 Santa Cruz Biotechnology), or anti-vinculin (1:1000,
Cell Signaling, Leiden, The Netherlands) was used for
immunoblotting. Densitometric analysis was performed
after reaction with ECL plus chemiluminescence kit from
Thermo-Fisher Scientiﬁc (Waltham, MA, USA) or Clarity
Max Western ECL Substrate-Luminol Solution (Biorad,
Hercules, CA, USA).
Statistical analysis
The statistical analysis of the values of bioluminescence
for the xenograft mice groups, as well as of Western
blots densitometry and luciferase activity values was
performed by analysis of variance. The number of
independent experiments has been indicated in the
Legends of the Figures. The data are shown as means ±
S.E., and their signiﬁcance was evaluated on the
original values in the case of fold-variations. P < 0.05 was
considered signiﬁcant. For xenograft mice, the survival
data were analyzed by Kaplan–Meier method and the
Log-rank (Mantel–Cox) test. P < 0.05 was considered
signiﬁcant.
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